Abbott announced on Friday that its Supera Peripheral Stent System has got the FDA's approval to treat blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). Last July, Abbott announced a $310 million deal to acquire Supera's developer, Texas-based Idev Technologies, which already had Supera before the FDA for review. The self-expanding nitinol stent already has a CE mark. In its U.S. trial, Idev brought data from 1,500 patients around the world. The disease, according to Abbott, affects 12% to 20% of Americans age 65 or over, causing leg pain and increased risk of blood clot or stroke. Supera is designed to mimic the body's natural function while propping open blood vessels. Release